Download the Interview
Explore how Nanopharm, a globally recognized Contract Research Organization (CRO), is becoming the inevitable choice for inhalation and nasal drug product development. Under the leadership of Gemma Budd, the new General Manager, Nanopharm has established itself as a Centre of Excellence in Orally Inhaled and Nasal Drug Products (OINDP). With its state-of-the-art, purpose-built facility, Nanopharm offers comprehensive inhalation services, characterized by an in-depth understanding of OINDP science, products, and test methods.
Nanopharm supports the entire clinical development process, ensuring efficient market realization and continuity for their clients. Their expertise in characterization services and tech transfer to CDMOs ensures a seamless path to market realization. As the company has grown, it has expanded its intellectual property and specialist knowledge, ensuring a legacy of innovation and mentorship from founders Dr Robert Price and Dr Jag Shur.
Nanopharm is dedicated to accelerating and de-risking the path to market for inhaled and nasal drug products, with a mindset focused on achieving the end goal of market readiness. Their partnership with Aptar Pharma, a leader in MDI and nasal spray technologies, enhances their capabilities, allowing them to work across various devices and platforms.
In a market that is evolving beyond asthma and COPD medications, Nanopharm is at the forefront of developing therapies for anti-infectives, CNS diseases, and cancer. Their Simhalation technology is revolutionizing the evaluation of molecules for nasal delivery, making them a key player in emerging therapeutic areas. With extensive knowledge in stability, solubility, compatibility, and device performance, Nanopharm provides partners with a significant advantage in bringing new molecules to market.
As Nanopharm matures, it continues to emphasize its role as a ‘go-to-market’ CRO, addressing challenges and providing solutions that move projects forward. With a clear understanding of the development process, Nanopharm helps partners navigate and succeed in bringing their products to market. Gemma Budd’s extensive career, including roles at AstraZeneca and Bespak, has equipped her with the expertise to lead Nanopharm into its next phase of growth. Her journey from biomedical science to product management and alliance management has given her a unique insight into the development and commercialization of OINDP devices.
